1035235-27-8

Basic information

• Product Name: tert-butyl-4-bromoisoindoline-2-carboxylate
• Synonyms: tert-butyl-4-bromoisoindoline-2-carboxylate;tert-Butyl 4-bromo-1,3-dihydro-2H-isoindole-2-carboxylate;2H-Isoindole-2-carboxylic acid, 4-bromo-1,3-dihydro-, 1,1-dimethylethyl ester;tert-butyl 4-bromo-2,3-dihydro-1H-isoindole-2-carboxylate;4-Bromo-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester;N-BOC-4-BROMOISOINDOLINE
• CAS NO: 1035235-27-8
• Molecular Formula: C₁₃H₁₆BrNO₂
• Molecular Weight: 298.17564
• Mol File: 1035235-27-8.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 363.218 °C at 760 mmHg
• Flash Point: 173.469 °C
• Appearance: /
• Density: 1.400
• Storage Temp.: 2-8°C
• PKA: -1.69±0.20(Predicted)
• CAS DataBase Reference: tert-butyl-4-bromoisoindoline-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl-4-bromoisoindoline-2-carboxylate(1035235-27-8)
• EPA Substance Registry System: tert-butyl-4-bromoisoindoline-2-carboxylate(1035235-27-8)

Safety Data

• Hazardous Substances Data: 1035235-27-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl-4-bromoisoindoline-2-carboxylate is a chemical compound that belongs to the class of carboxylic acid esters. It contains the functional groups tert-butyl, bromo, and isoindoline, which contribute to its chemical properties and reactivity. Tert-butyl-4-bromoisoindoline-2-carboxylate is commonly used as a building block in organic synthesis and medicinal chemistry. It can be utilized in the preparation of various organic molecules such as pharmaceuticals, agrochemicals, and functional materials. Tert-butyl-4-bromoisoindoline-2-carboxylate is a valuable and versatile chemical that has applications in a wide range of industries and research fields.

Upstream product

• 127168-81-4 4-bromoisoindoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 923590-95-8 4-bromo-2,3-dihydro-1H-isoindole hydrochloride 

Downstream Products

• 1035235-28-9 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindoline-2-carboxylic acid tert-butyl ester 
• 923591-06-4 methyl (1R,21S,24S)-21-tert-butyl-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.1(4,7).0(6,11)]heptacosa-6,8,10-triene-24-carboxylate 
• 923590-95-8 4-bromo-2,3-dihydro-1H-isoindole hydrochloride 
• 1049677-40-8 tert-butyl 4-formyl-1,3-dihydro-2H-isoindole-2-carboxylate 
• 1311254-56-4 tert-butyl 4-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxylate 
• 1165876-20-9 1,1-dimethylethyl 4-cyano-1,3-dihydro-2H-isoindole-2-carboxylate 
• 1159825-57-6 C₉H₈N₂*ClH 
• 1311254-39-3 2-(tert-butyl) 4-ethyl isoindoline-2,4-dicarboxylate 
• 127168-73-4 4-methoxy-1H-isoindole 
• 871013-92-2 tert-butyl 4-hydroxy-1,3-dihydro-2H-isoindole-2-carboxylate 
• 1434816-15-5 4-[(S)-1-(2,4-difluoro-3-phenoxy-phenyl)-propylamino]-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester 

Relevant articles and documents

Phase Separation Macrocyclization in a Complex Pharmaceutical Setting: Application toward the Synthesis of Vaniprevir

A phase separation/continuous flow strategy employing an oxidative Glaser-Hay coupling of alkynes has been applied toward the synthesis of the macrocyclic core of complex pharmaceutical vaniprevir. The phase separation/continuous flow strategy afforded similar yields at 100-500 times the concentration and at shorter reaction times than common slow addition/high dilution techniques. In addition, dendritic PEG cosolvents were employed in the phase separation strategy for the first time and shown to allow productive macrocyclization at concentrations up to 200 mM.

SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Disclosed are 7-phenyl-2-aminoquinoline compounds that are shown to inhibit the biological activity of neuronal nitric oxide synthases (nNOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and

FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS

The present invention is directed to a composition and a method for use thereof, such as for the treatment and prevention of a neurological disorder or cancer in a subject.